Type Name/Description Filesize Download
application/pdf icon
General Capabilities
PharmOptima's proven approach to drug discovery and optimization focuses on our ability to maximize your program's success by developing customized solutions for your intellectual property problems and providing the highest quality data in a rapid timeframe to move your compound up the value chain. Founded by scientists with broad expertise and years of pharmaceutical experience, we truly understand the value of solving the complex problems associated with drug development. Our multidisciplinary scientific team consults with you to provide research strategies to optimize your success.
581.61 KB General Capabilities
application/pdf icon
Biomarker and Assay Capabilities
PharmOptima provides custom assay development services to customers worldwide. PharmOptima scientists have extensive experience in multiple assay development platforms. Our staff will work with you to develop assays to meet your specific research needs.In many cases biomarkers are available from human, rat, mouse and non-human primate. We have the expertise and experience to clone and express proteins if what you need is not commercially available.
391.41 KB Biomarker and Assay Capabilities
application/pdf icon
Ocular Capabilities
PharmOptima's ophthalmic services begin, run and conclude with a high level of technical expertise. From specialized ocular dosing by trained scientists, to the precise dissection of specific ocular tissues by our specialists, followed by exacting sample processing and bioanalysis by PharmOptima's experienced staff; we stand out against the large CRO model of generalized necropsy technicians and crash & shoot discovery bioanalysis. PharmOptima's bioanalytical team has extensive experience processing, homogenizing and extracting ocular fluids and tissues. We have developed LC-MS/MS methods for hundreds of compounds.
439.6 KB Ocular Capabilities
application/pdf icon
14 Day Rat Nephrotoxicity Study with Kidney Injury Biomarkers
Biomarkers panel identified gentamicin, at the dose tested, as a nephrotoxin as early as only 3 days of administration. Traditional clinical markers of kidney toxicity, Serum Creatinine and BUN, would not have identified gentamicin, at the dose tested, as a nephrotoxin even after 14 days of administration. PharmOptima's ECL Biomarker Nephrotoxicity Testing is: - Cost effective method - Faster than traditional histopathology method - More sensitive than traditional clinical markers Call or email for more information or a quote
534.37 KB 14 Day Rat Nephrotoxicity Study with Kidney Injury Biomarkers
application/pdf icon
SMN in Whole Blood Assay
PharmOptima's proprietary SMN assay allows for the measurement of SMN protein in whole blood, requiring as little as 5μl whole blood. Statistically significant differences noted between Type 2 patients and carriers.
785.39 KB SMN in Whole Blood Assay